A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes.

The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.

开始日期2026-10-01

申办/合作机构

Eli Lilly & Co.

NCT07808060

/ Not yet recruiting临床1期

A Phase 1, Open-Label Study to Evaluate the Effect of Eloralintide on the Pharmacokinetics of the Combined Oral Contraceptive Levonorgestrel-Ethinyl Estradiol in Female Participants With Obesity or Overweight

The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.

开始日期2026-09-01

申办/合作机构

Eli Lilly & Co.

NCT07738614

/ Recruiting临床1期

A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

开始日期2026-07-31

申办/合作机构

Eli Lilly & Co.

100 项与艾洛林肽相关的临床结果

登录后查看更多信息

100 项与艾洛林肽相关的转化医学

登录后查看更多信息

100 项与艾洛林肽相关的专利（医药）

登录后查看更多信息

项与艾洛林肽相关的文献（医药）

2026-10-01·PHARMACOLOGICAL RESEARCH

Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

Review

作者: Borner, Tito ; Fischer, Sophia L

Amylin-based pharmacotherapy has re-emerged as a promising strategy for the treatment of obesity and metabolic disease with pharmacological and neural mechanisms distinct from incretin-based therapies. Amylin is a pancreatic β-cell hormone co-secreted with insulin that contributes to postprandial glucose regulation, slows gastric emptying, suppresses glucagon secretion, and promotes satiation through actions in the central nervous system. Recent advances in peptide engineering, lipidation, and reversible albumin binding have enabled the development of long-acting amylin-based agents, including cagrilintide, eloralintide, petrelintide and NN1213. These therapies differ in their pharmacokinetic properties and receptor selectivity, ranging from more selective amylin receptor agonists to dual amylin/calcitonin receptor agonists. This distinction may be critical for understanding both efficacy and tolerability, as calcitonin receptor engagement, exposure kinetics, and downstream neural circuit recruitment may influence whether reduced food intake reflects physiological satiation or aversive signaling. In this review, we summarize the biology of amylin signaling, the historical development of amylin-based therapeutics, and the emerging clinical landscape of long-acting amylin analogs. We place particular emphasis on the tolerability profile of this drug class and discuss how receptor pharmacology, hindbrain and parabrachial circuitry, species differences, and pharmacokinetic exposure may shape nausea, malaise, and emesis. Understanding how amylin-based therapies dissociate weight-loss efficacy from gastrointestinal intolerance may guide the rational design of next-generation anti-obesity drugs with improved clinical utility.

2026-05-01·Endocrinology, diabetes & metabolism

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis

Review

作者: Khalil, Ibrahim ; Kamrul‐Hasan, A. B. M. ; Dutta, Deep ; Mahajan, Kunal ; Pappachan, Joseph M. ; Banerjee, Mainak

ABSTRACT:

Background:

Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta‐analysis (NMA) framework.

Methods:

We conducted a frequentist random‐effects NMA of randomized controlled trials comparing novel ABTs with placebo or active comparators in R. Primary outcome was the percent change in body weight from baseline. Secondary outcomes included absolute weight changes, anthropometric measures, and overall and specific GI adverse events (AEs). Treatments (including dose strata) were compared with placebo within a single network and ranked using P scores.

Results:

Six trials ( N = 4642; 12–68 weeks) were included. Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference −23.95%; P score 1.00), followed by HiD eloralintide (−18.01%; P score 0.89) and HiD CagriSema (−17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (−11.45%) and liraglutide 3.0 mg (−6.4%). Almost similar patterns were observed for absolute weight, body mass index, waist circumference and categorical weight‐loss thresholds. GI AEs, nausea, vomiting and constipation were more common with HiD ABTs, especially oral amycretin and CagriSema, while diarrhoea mainly increased with semaglutide 2.4 mg. Only HiD CagriSema increased AE‐related discontinuation.

Conclusions:

Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short‐ to medium‐term weight loss but may also increase GI AEs; given sparse, low‐certainty data, these findings are preliminary and require confirmation in larger trials.

Trial Registration:

The meta‐analysis was registered in PROSPERO (CRD420261340457). The review protocol summary can be accessed at the PROSPERO website ( https://www.crd.york.ac.uk/PROSPERO/view/CRD420261340457 )

2026-04-01·DIABETES OBESITY & METABOLISM

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

Article

作者: Lai San Tham PharmD ; Edward Pratt MD ; Daniel A. Briere MS ; Hilda Ibriga PhD ; Kieren J. Mather MD ; Hongchang Qu PhD ; Axel Haupt MD ; Shobha Bhattachar MS ; Beth Tidemann-Miller PhD

Abstract:

Aim:

Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing.

Materials and Methods:

This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic profiles of eloralintide upon once‐weekly subcutaneous dosing without dose escalation in participants with obesity or overweight.

Results:

From 30 March 2022 to 25 January 2024, at three centres in the United States, 100 participants with a mean age of 44 years, 29% female participants, and mean body mass index of 32.6 kg/m 2 , were randomly assigned to receive either eloralintide or placebo in 5 multiple ascending dose cohorts. At Week 12, AUC τ,ss and C max were dose proportional with ratios of dose‐normalised geometric means of 1.1 and 1.0, respectively. The most common treatment‐emergent adverse events (TEAEs) with eloralintide included decreased appetite (19% of participants), headache (12%), fatigue (11%), and COVID‐19 (11%). Gastrointestinal adverse events, including diarrhoea (10% of participants), nausea (8%), and vomiting (4%), were infrequent in those receiving eloralintide. Most TEAEs were mild in severity. No deaths and one serious adverse event (in the 6 mg eloralintide cohort) unrelated to eloralintide occurred. At Week 12 with eloralintide, the least squares mean percent reduction in body weight across the dose groups ranged from 2.6% to 11.3%.

Conclusion:

Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss.

181

项与艾洛林肽相关的新闻（医药）

2026-10-08

·Firstwordpharma

Zealand touts another weight-loss win for petrelintide, but HbA1c results fail to stand out

A week after sharing detailed data from a mid-stage obesity study of petrelintide, Roche and Zealand Pharma have posted Phase II findings for the amylin analogue in patients with type 2 diabetes. While petrelintide met its weight-loss primary endpoint, its effect on HbA1c levels failed to impress, as the company's shares ticked down about 5% on Wednesday. The latest readout comes from the Phase II ZUPREME-2 trial involving 220 people with overweight or obesity and type 2 diabetes who were randomised to receive one of three dose levels of petrelintide injection — escalated every fourth week — or placebo. Participants had a mean baseline BMI of 36.3 kg/m2 and a mean baseline HbA1c of 8%. After 28 weeks, patients taking petrelintide achieved up to 9.2% mean weight loss from baseline, based on the efficacy estimand, compared with 2% for placebo.The results are roughly in line with the Phase II ZUPREME-1 trial of the amylin analogue, which enrolled patients with obesity, without diabetes. Updated data, presented at the European Association for the Study of Diabetes (EASD) meeting last week, showed mean weight reductions from baseline reached up 9.8% at week 28. Petrelintide also achieved a tolerability profile similar to placebo. The most common adverse events (AEs) in ZUPREME-2 associated with the experimental treatment were gastrointestinal (GI), though "the vast majority" were mild, the drugmaker said. Patients taking the amylin analogue had a treatment discontinuation rate due to GI AEs of 1.9% versus 1.7% with placebo. Blood sugar impact?For a key diabetes-specific endpoint, Zealand said petrelintide demonstrated clinically relevant, placebo-adjusted HbA1c reductions ranging from 0.61% to 0.88% across all dosing groups. Eli Lilly and Novo are both developing co-formulations of their respective flagship GLP-1 drugs with an amylin-targeting component; the former's EloraTZP adds amylin receptor agonist eloralintide to GLP-1/GIP agonist tirzepatide, while Novo's CagriSema comprises semaglutide and cagrilintide, a long-acting amylin analogue. While recent readouts for EloraTZP and CagriSema aren't directly comparable to petrelintide, they're illustrative of the HbA1c reductions investors are hoping to see in diabetes studies. At EASD, Lilly reported data from a Phase IIb study of EloraTZP demonstrating a placebo-adjusted 2.6% reduction in HbA1c for the highest tested dose at week 48 (see – KOL Views Q&A: Amylin could fill gaps where GLP-1s fall short).Earlier in September, Novo shared 60-week findings from the Phase III REIMAGINE 5 trial showing a 1.71-percentage-point reduction in HbA1c for CagriSema (see – Physician Views Results: Novo's CagriSema wins clinician enthusiasm in diabetes — but access and Lilly's tirzepatide loom large).Zealand said full results from ZUPREME-2 will be shared at an upcoming meeting; a Phase III programme evaluating petrelintide monotherapy for chronic weight management is already under way.

临床2期临床结果临床3期

2026-10-08

·BioSpace

Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers

iStock, Marharyta Kovalchuk For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide. Zealand Pharma’s Roche-partnered obesity asset cut weight to a degree William Blair analysts dubbed “intriguing,” but the asset “underwhelmed” on blood sugar reduction for diabetes. The mid-stage readout was the second from Zealand’s pipeline of next-gen weight loss assets to disappoint investors in a week. In the Phase 2 ZUPREME-2 trial, petrelintide, a long-acting human amylin analog, achieved up to 9.2% mean weight loss at week 28 depending on the dose, compared to just 2% for placebo comparators, according to Zealand’s Thursday press release . The study, which featured 220 patients with obesity or overweight who also had type 2 diabetes (T2D), therefore hit its primary endpoint of statistically significant and clinically meaningful reductions in body weight at that time point, compared to placebo. The results—which were based on efficacy estimand, or the estimated treatment effect assuming patients remained on treatment for the duration of the study—are in line with Eli Lilly’s rival amylin receptor agonist eloralintide and the approved GLP-1 Zepbound, William Blair analysts said in a Wednesday afternoon note. Both of those drugs achieved about 7% placebo-adjusted weight loss at the same time point, according to the firm. Meanwhile, Zealand’s asset outperformed Novo’s Wegovy, which notched 4–5% weight loss in that time frame. Nevertheless, William Blair analysts said they were “disappointed” the asset did not yield greater weight loss. Moreover, petrelintide only reduced A1C, a measure of average blood sugar levels that is used as key marker of disease control in T2D, at a rate of up to 0.65% compared to an increase of 0.23% for placebo participants, according to Zealand’s release. The aforementioned rival therapies achieved A1C reductions within a range of 1.3%–2.1%, William Blair said. The firm was also concerned by the increase seen in the placebo arm, which is “unusual in the context of obesity and/or T2D studies.” On a more positive note, safety results were as expected, leaving William Blair with continued conviction in the asset’s differentiated tolerability profile. Gastrointestinal-related adverse events did crop up, but most were mild and occurred during the escalation period, and resulted in a discontinuation rate due of just 1.9% of participants in the treatment arm, versus 1.7% of those taking placebo. The therapy seems to provide “an improved treatment experience” over approved weight loss drugs like Wegovy and Zepbound, the analysts said. “Overall, based on the collective Phase II ZUPREME-1 and ZUPREME-2 trial results, we believe petrelintide demonstrated highly encouraging tolerability, though the magnitude of weight loss (along with HbA1c reduction in ZUPREME-2) disappointed,” William Blair wrote. “Our current view is that petrelintide will likely be used primarily in the maintenance setting, which demands a therapeutic intervention that exhibits placebo-like tolerability for chronic use.” Petrelintide could also find a foothold in the overweight segment of the market, helping these patients lose weight without safety concerns and improve cardiovascular risk, the firm added. The ZUPREME-2 reveal comes a week after Zealand and partner Boehringer Ingelheim reported disappointing Phase 3 weight loss results for the glucagon/GLP-1 receptor dual agonist survodutide. Similar to the new petrelintide readout, survodutide underperformed expectations. The company reported weight loss of up to 13.1% at 76 weeks, but an adjacent publication in The New England Journal of Medicine put the value at 9.8% for patients who received the highest dose. Shares of Zealand dropped more than 8% to $248.50 on the Danish market following last week’s results, and trended further down today, resting at around $240 as of publication. Obesity Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors. October 1, 2026 · 2 min read · Heather McKenzie Read more The mixed results won’t hold back petrelintide, however. Zealand and Roche recently kicked off a Phase 3a program for the asset. ZUPREME-3, ZUPREME-4 and ZUPREME-5 will include 7,000 patients with obesity or overweight without T2D, with T2D and with cardiovascular disease, respectively. But after a busy few weeks of readouts, investors will have to wait a while for the next big catalyst for Zealand, William Blair pointed out. The company does have a strong cash position, share buyback program and a deep pipeline. “While we believe these factors should support long‑term value creation and eventual share price appreciation, the lack of meaningful catalysts within the next year that could alter investor sentiment on petrelintide limits near-term upside and supports a more balanced risk/reward profile,” the firm wrote. Roche licensed petrelintide in March 2025 to pair with its own dual GLP-1/GIP receptor agonist CT-388. The deal offered Zealand $1.65 billion upfront, while the total deal value, including milestones and other payments, could reach $5.3 billion.

临床2期临床结果临床3期

2026-10-07

·药事纵横

EASD ：替尓泊肽的复方制剂减重和降糖均优于单方

2026 年 9 月 30 日，礼来公司公布了一项2b期试验的阳性结果。该试验评估了 EloraTZP 的安全性和有效性。EloraTZP 是一种研究性组合疗法，由选择性胰淀素受体激动剂埃洛拉林肽（eloralintide）和双重GIP/GLP-1受体激动剂替尔泊肽组成，研究对象为367名肥胖或超重合并2型糖尿病的成人。在第48周时，所有 EloraTZP 联合剂量组均达到了主要和次要终点，实现了显著的减重和A1C降幅。该试验的结果已在意大利米兰举行的第62届欧洲糖尿病研究协会（EASD）年会上公布。 EloraTZP 的开发旨在同时激活三种互补的营养刺激激素：GIP、GLP-1 和胰淀素，同时对降钙素受体的活性极低。这些物质在进食后由人体自然释放，每种物质通过其自身独特的受体发挥作用，帮助调节饥饿感和血糖。伊利诺伊州埃文斯顿 Endeavor Health 糖尿病与心脏代谢疾病临床与遗传学研究主任、本研究的牵头作者 Liana K. Billings 医学博士表示：“肥胖和2型糖尿病是相互关联的，我们看到了靶向多种激素通路来同时应对这两者的潜在益处。在所研究的埃洛拉林肽与替尔泊肽的各种剂量组合中，参与者在实现大幅减重的同时，A1C 也获得了有意义的降低。这些是对患者至关重要的结果。我们需要在这些发现的基础上继续努力，以便将来能够为患者提供更多的治疗选择，同时解决体重和血糖问题，并更好地反映2型糖尿病和肥胖症患者生活的复杂性。” 埃洛拉林肽单药治疗使体重平均降低最高达 28.6 磅（12.3%），A1C 平均降低最高达 1.4%；而替尔泊肽 15 mg 使体重平均降低 34.4 磅（14.8%），A1C 降低 2.4%。在第48周时，服用 EloraTZP 的患者体重平均降低最高达 54.1 磅（23.3%），A1C 平均降低最高达 2.9%，效果超过了任一单药治疗。2b期疗效估计目标结果主要终点为 EloraTZP 与安慰剂相比的体重百分比变化。所有其他比较均为次要终点。最常见的不良事件为胃肠道相关，通常为轻度或中度，主要发生在剂量递增期间。这些事件在联合治疗组的发生率高于埃洛拉林肽或替尔泊肽单药组。因不良事件导致的治疗中止率：EloraTZP 组为 10.8% 至 27.0%，埃洛拉林肽组为 0% 至 10.8%，替尔泊肽组为 2.9%，安慰剂组为 16.7%。礼来心脏代谢健康业务执行副总裁兼总裁 Kenneth Custer 博士表示：“礼来继续为肥胖和糖尿病患者开拓新的药物，这建立在我们在替尔泊肽（首个获批的GIP和GLP-1双激动剂）以及我们的研究性三激动剂 retatrutide 的科学成就之上。EloraTZP 代表了我们的下一个前沿领域，它将选择性胰淀素受体激动剂与替尔泊肽配对，这可能是一种更具叠加性、更符合生理学原理的代谢健康管理方法。我们对 EloraTZP 的2期结果感到非常鼓舞，并期待迅速启动3期研究。” 埃洛拉林肽作为单药治疗肥胖症的3期试验正在进行中。礼来计划在2026年底前启动 EloraTZP 复方制剂的3期研究，并使用优化的剂量递增方案。关于 EloraTZP EloraTZP 是一种研究性组合疗法，由选择性胰淀素受体激动剂埃洛拉林肽和双重GIP/GLP-1受体激动剂替尔泊肽（Zepbound 和 Mounjaro 的活性成分）组成。通过同时激活胰淀素和肠促胰素通路，EloraTZP 有潜力通过人体自然的代谢信号来改善体重和血糖。在这项2b期研究（NCT06603571）中，埃洛拉林肽和替尔泊肽以独立注射的方式给予肥胖或超重合并2型糖尿病的成人。礼来计划在2026年底前将 EloraTZP 复方制剂推进至3期。关于埃洛拉林肽（eloralintide）埃洛拉林肽是一种研究性、每周一次的选择性胰淀素受体激动剂，此前代号为 LY3841136。埃洛拉林肽有潜力减少热量摄入，其效应可能通过影响饱腹感（即充盈感）来介导。目前正在进行埃洛拉林肽治疗肥胖症以及在肥胖或超重合并或不合并2型糖尿病的成人中的3期试验。礼来还开展了一项2b期研究（NCT06230523），比较每周一次的埃洛拉林肽与安慰剂在肥胖或超重且至少有一种体重相关合并症但不合并2型糖尿病的成人中的疗效和安全性⁵。关于 Zepbound（替尔泊肽）注射液 Zepbound（替尔泊肽）是首个且唯一的双重GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高血糖素样肽-1）受体激动剂类肥胖药物。Zepbound 针对体重超标的一个根本原因起作用。它能降低食欲和进食量。Zepbound 适用于肥胖成人，或部分超重且至少有一种体重相关医疗问题的成人，以减轻多余体重并维持体重。此外，Zepbound 已获得FDA批准，用于治疗中度至重度阻塞性睡眠呼吸暂停合并肥胖的成人。Zepbound 应与低热量饮食和增加体力活动配合使用。立即扫码加入药事纵横交流群

100 项与艾洛林肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12886	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	临床3期	美国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	中国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	日本	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	澳大利亚	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	巴西	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	加拿大	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	德国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	印度	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	韩国	Eli Lilly & Co.	2026-02-10
阻塞性睡眠呼吸暂停综合征	临床3期	西班牙	Eli Lilly & Co.	2026-02-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06230523 (CTgov)	临床2期	肥胖	263	Placebo (Placebo)	遞淵壓蓋製積選艱觸網(鏇醖鑰簾選壓選餘選繭) = 築鑰壓廠願窪淵選鏇網鏇範選鏇襯夢夢鏇蓋鹽 (獵網艱襯艱艱獵構齋憲, 0.91) 更多	-	2026-06-24
				Eloralintide (1 mg Eloralintide)	遞淵壓蓋製積選艱觸網(鏇醖鑰簾選壓選餘選繭) = 窪鬱襯夢製齋網蓋憲壓鏇範選鏇襯夢夢鏇蓋鹽 (獵網艱襯艱艱獵構齋憲, 1.60) 更多
NCT06230523 (Pubmed \| Lancet)	临床2期	肥胖	263	Eloralintide 1 mg	夢積蓋觸醖獵鬱積艱製(構襯窪淵網願壓觸鑰壓) = 鑰鏇構積憲遞夢鹽憲糧觸廠觸獵膚窪壓網築鏇 (鹹製鏇醖築顧蓋選觸糧, -12.6 ~ -6.3)	积极	2025-12-01
				Eloralintide 3 mg	夢積蓋觸醖獵鬱積艱製(構襯窪淵網願壓觸鑰壓) = 窪膚糧遞積蓋齋夢選遞觸廠觸獵膚窪壓網築鏇 (鹹製鏇醖築顧蓋選觸糧, -14.9 ~ -9.8)
NCT05295940 (Pubmed \| Mol Metab)	临床1期	肥胖	48	Eloralintide	衊願製網繭膚積鬱範鏇(憲構窪構積窪艱築範醖) = 遞鏇淵齋鑰憲範構鹹網鏇顧顧繭簾廠觸夢壓範 (淵夢蓋艱襯艱網餘鏇範 ) 更多	积极	2025-12-01
				Placebo	鹽壓淵襯築範遞獵窪鹽(夢憲窪範鹽齋艱艱製網) = 廠遞鬱夢鬱衊襯簾鹹觸廠顧餘夢構餘製範壓糧 (餘鹹遞衊選範醖顧獵鏇 ) 更多
NCT06230523 (Company_Website \| Lancet) 人工标引	临床2期	超重 \| 肥胖	263	Eloralintide 1 mg	願繭範鬱鹹夢獵醖淵鏇(製艱顧範襯糧鑰鏇繭蓋) = 網膚淵範簾衊網積築鬱鹽積鏇夢蓋製製鬱簾遞 (鹽壓繭蓋繭顧選壓觸夢 ) 达到	积极	2025-11-06
				Eloralintide 3 mg	願繭範鬱鹹夢獵醖淵鏇(製艱顧範襯糧鑰鏇繭蓋) = 鹽顧鏇糧夢範網醖齋夢鹽積鏇夢蓋製製鬱簾遞 (鹽壓繭蓋繭顧選壓觸夢 ) 达到
NCT06916091 (ADA2025 \| NEWS) 人工标引	临床1期	肥胖	100	Eloralintide dose1	繭窪鹽鏇繭觸選糧壓餘(網簾壓鏇願鹽蓋衊鬱築) = 鹽鹹製窪範廠壓壓襯範鹽選簾窪製蓋餘構繭艱 (夢範醖選餘鏇選淵淵壓 ) 更多	积极	2025-06-17
				Eloralintide dose2	築衊遞願糧艱鏇鹽衊繭(壓簾網築顧廠網膚鹹壓) = 願夢淵願鬱製簾繭網選鹹醖齋繭壓壓願範鑰簾 (鏇鏇鏇積範構蓋醖醖願 )